Shanghai Bioxin Biotechnology Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 63

Employees

  • Stock Symbol
  • 02185

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $0.11
  • (As of Friday Closing)

Shanghai Bioxin Biotechnology General Information

Description

Shanghai Bio-heart Biological Technology Co Ltd is engaged in the research and development of bioresorbable scaffold (BRS) products and the renal denervation (RDN) system. The company is a interventional cardiovascular device company in China, and locate in Shanghai Zhangjiang Hi-Tech Park Medical Device Industrial Park. Focused on two therapies, bioresorbable scaffolds (BRS) and renal denervation (RDN), addressing the unmet medical needs of Chinese patients for the treatment of coronary and peripheral artery diseases and uncontrolled hypertension. Currently, the portfolio has three product candidates in various stages of clinical development.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • No. 59 Kaiqing Road, Pudong New Area
  • 4th Floor, Building 7
  • Shanghai, 201201
  • China
+86 021
Primary Industry
Biotechnology
Stock Exchange
HKG
Vertical(s)
Corporate Office
  • No. 59 Kaiqing Road, Pudong New Area
  • 4th Floor, Building 7
  • Shanghai, 201201
  • China
+86 021

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Shanghai Bioxin Biotechnology Stock Performance

As of 13-Nov-2026, Shanghai Bioxin Biotechnology’s stock price is $0.11. Its current market cap is $27.9M with 243M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.11 $0.12 $0.11 - $1.00 $27.9M 243M 87K -$0.04

Shanghai Bioxin Biotechnology Financials Summary

As of 30-Jun-2026, Shanghai Bioxin Biotechnology has a trailing 12-month revenue of $5.49M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 67,760 154,838 16,967 58,630
Revenue 5,495 6,248 0 0
EBITDA (10,415) (9,886) (12,012) (24,154)
Net Income (10,790) (9,741) (12,256) (24,862)
Total Assets 116,395 118,982 100,516 115,382
Total Debt 1,697 1,819 1,135 249
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Shanghai Bioxin Biotechnology Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Shanghai Bioxin Biotechnology‘s full profile, request access.

Request a free trial

Shanghai Bioxin Biotechnology Patents

Shanghai Bioxin Biotechnology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240226011-A1 Core-shell micelle microsphere, and preparation method therefor and use thereof Pending 28-Dec-2022
EP-4643853-A1 Core-shell structure micellar microsphere, preparation method therefor, and use thereof Pending 28-Dec-2022
EP-4643853-A4 Core-shell structure micellar microsphere, preparation method therefor, and use thereof Pending 28-Dec-2022
WO-2024138798-A1 Core-shell structure micellar microsphere, preparation method therefor, and use thereof Inactive 28-Dec-2022
JP-2025503347-A Core-shell structured micellar microspheres and preparation method and use thereof Active 28-Dec-2022 A61K9/167
To view Shanghai Bioxin Biotechnology’s complete patent history, request access »

Shanghai Bioxin Biotechnology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Shanghai Bioxin Biotechnology Investments & Acquisitions (3)

Shanghai Bioxin Biotechnology’s most recent deal was a Corporate with ContiTech (Diagnostic Equipment) for . The deal was made on 07-Sep-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ContiTech (Diagnostic Equipment) 07-Sep-2022 Corporate Diagnostic Equipment
Xinzhi Medical 22-Jun-2022 Later Stage VC Therapeutic Devices
Angio Care China 23-Sep-2020 Merger/Acquisition Other Devices and Supplies
To view Shanghai Bioxin Biotechnology’s complete investments and acquisitions history, request access »

Shanghai Bioxin Biotechnology ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Commercial Services

Industry

Rank

Percentile

Business Support Services

Subindustry

Rank

Percentile

To view Shanghai Bioxin Biotechnology’s complete esg history, request access »

Shanghai Bioxin Biotechnology Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Angio Care China Shanghai, China 2011

Shanghai Bioxin Biotechnology FAQs

  • When was Shanghai Bioxin Biotechnology founded?

    Shanghai Bioxin Biotechnology was founded in 2014.

  • Where is Shanghai Bioxin Biotechnology headquartered?

    Shanghai Bioxin Biotechnology is headquartered in Shanghai, China.

  • What is the size of Shanghai Bioxin Biotechnology?

    Shanghai Bioxin Biotechnology has 63 total employees.

  • What industry is Shanghai Bioxin Biotechnology in?

    Shanghai Bioxin Biotechnology’s primary industry is Biotechnology.

  • Is Shanghai Bioxin Biotechnology a private or public company?

    Shanghai Bioxin Biotechnology is a Public company.

  • What is Shanghai Bioxin Biotechnology’s stock symbol?

    The ticker symbol for Shanghai Bioxin Biotechnology is 02185.

  • What is the current stock price of Shanghai Bioxin Biotechnology?

    As of 13-Nov-2026 the stock price of Shanghai Bioxin Biotechnology is $0.11.

  • What is the current market cap of Shanghai Bioxin Biotechnology?

    The current market capitalization of Shanghai Bioxin Biotechnology is $27.9M.

  • What is Shanghai Bioxin Biotechnology’s current revenue?

    The trailing twelve month revenue for Shanghai Bioxin Biotechnology is $5.49M.

  • What is Shanghai Bioxin Biotechnology’s annual earnings per share (EPS)?

    Shanghai Bioxin Biotechnology’s EPS for 12 months was -$0.04.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process